Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 190

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

Open access
Puig-Saus, Cristina, Sennino, Barbara, Peng, Songming, Wang, Clifford L., Pan, Zheng, Yuen, Benjamin, Purandare, Bhamini, An, Duo, Quach, Boi B., Nguyen, Diana, Xia, Huiming, Jilani, Sameeha, Shao, Kevin, McHugh, Claire, Greer, John, Peabody, Phillip, Nayak, Saparya, Hoover, Jonathan, Said, Sara, Jacoby, Kyle, Dalmas, Olivier, Foy, Susan P., Conroy, Andrew, Yi, Michael C., Shieh, Christine, Lu, William, Heeringa, Katharine, Ma, Yan, Chizari, Shahab, Pilling, Melissa J., Ting, Marc, Tunuguntla, Ramya, Sandoval, Salemiz, Moot, Robert, Hunter, Theresa, Zhao, Sidi, Saco, Justin D., Perez-Garcilazo, Ivan, Medina, Egmidio, Vega-Crespo, Agustin, Baselga-Carretero, Ignacio, Abril-Rodriguez, Gabriel, Cherry, Grace, Wong, Deborah J., Hundal, Jasreet, Chmielowski, Bartosz, Speiser, Daniel E., Bethune, Michael T., Bao, Xiaoyan R., Gros, Alena, Griffith, Obi L., Griffith, Malachi, Heath, James R., Franzusoff, Alex, Mandl, Stefanie J., Ribas, Antoni · 2023 · Nature

Abstract

Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T cells^ 1 – 14 . The large HLA allele diversity and limiting clinical samples have restricted the study of the landscape of neoantigen-targeted T cell responses in patients over their treatment course. Here we applied recently developed technologies^ 15 – 17 to capture neoantigen-specific T cells from blood and tumours from patients with metastatic melanoma with or without response to anti-programmed death receptor 1 (PD-1) immunotherapy. We generated personalized libraries of neoantigen–HLA capture reagents to single-cell isolate the T cells and clone their T cell receptors (neoTCRs). Multiple T cells with different neoTCR sequences (T cell clonotypes) recognized a limited number of mutations in samples from seven patients with long-lasting clinical responses. These neoTCR clonotypes were recurrently detected over time in the blood and tumour. Samples from four patients with no response to anti-PD-1 also demonstrated neoantigen-specific T cell responses in the blood and tumour to a restricted number of mutations with lower TCR polyclonality and were not recurrently detected in sequential samples. Reconstitution of the neoTCRs in donor T cells using non-viral CRISPR–Cas9 gene editing demonstrated specific recognition and cytotoxicity to patient-matched melanoma cell lines. Thus, effective anti-PD-1 immunotherapy is associated with the presence of polyclonal CD8^+ T cells in the tumour and blood specific for a limited number of immunodominant mutations, which are recurrently recognized over time. Effective anti-PD-1 immunotherapy is associated with the presence of polyclonal CD8^+ T cells in the tumour and blood specific for a limited number of immunodominant mutations, which are recurrently recognized over time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-023-05787-1

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 190

Metadata

Authors
Puig-Saus, C., Sennino, B., Peng, S., Wang, C. L., Pan, Z., Yuen, B., Purandare, B., An, D., Quach, B. B., Nguyen, D., Xia, H., Jilani, S., Shao, K., McHugh, C., Greer, J., Peabody, P., Nayak, S., Hoover, J., Said, S., Jacoby, K., Dalmas, O., Foy, S. P., Conroy, A., Yi, M. C., Shieh, C., Lu, W., Heeringa, K., Ma, Y., Chizari, S., Pilling, M. J., Ting, M., Tunuguntla, R., Sandoval, S., Moot, R., Hunter, T., Zhao, S., Saco, J. D., Perez-Garcilazo, I., Medina, E., Vega-Crespo, A., Baselga-Carretero, I., Abril-Rodriguez, G., Cherry, G., Wong, D. J., Hundal, J., Chmielowski, B., Speiser, D. E., Bethune, M. T., Bao, X. R., Gros, A., Griffith, O. L., Griffith, M., Heath, J. R., Franzusoff, A., Mandl, S. J., & Ribas, A.
Venue
Nature
Published
2023-03-08
Volume
615
Issue
7953
Pages
697-704
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4323546617
Cited by
190
References
12
FWCI
20.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. https://app.cochat.ai/papers/10.1038/s41586-023-05787-1
The paper
Puig-Saus, C., Sennino, B., Peng, S., Wang, C. L., Pan, Z., Yuen, B., Purandare, B., An, D., Quach, B. B., Nguyen, D., Xia, H., Jilani, S., Shao, K., McHugh, C., Greer, J., Peabody, P., Nayak, S., Hoover, J., Said, S., . . . Ribas, A. (2023). Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature. https://doi.org/10.1038/s41586-023-05787-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.